CHADS2, CHA2DS2-VASc, and long-term stroke outcome in patients without atrial fibrillation

Objective: CHADS2 and CHA2DS2-VASc scores are used to assess stroke risk in patients with atrial fibrillation (AF). We investigated whether these scores are associated with stroke outcome in non-AF stroke patients. Methods: Consecutive patients with acute first-ever ischemic stroke but without AF were classified into subgroups according to prestroke CHADS2 and CHA2DS2-VASc scores and followed up for 5 years. The end points were death, stroke recurrence, and a composite of major cardiovascular events. Results: Among 1,756 patients (aged 67.2 ± 12.3 years, 68.2% males), there were 258 (14.7%), 617 (35.3%), and 878 (50.0%) patients with low, intermediate, and high CHADS2 score, respectively. The corresponding figures for CHA2DS2-VASc subgroups were 110 (6.3%), 255 (14.5%), and 1,391 (79.2%). There were significant differences between CHADS2 subgroups in 5-year mortality (log-rank test = 74.5, p < 0.0001), stroke recurrence (log-rank test = 12.3, p = 0.002), and cardiovascular events (log-rank test = 19.4, p < 0.001). Similarly, there were significant differences between CHA2DS2-VASc subgroups in 5-year mortality (log-rank test = 74.5, p < 0.0001), stroke recurrence (log-rank test = 10.6, p = 0.005), and cardiovascular events (log-rank test = 16.4, p < 0.001). Compared with the low-risk group, patients in intermediate- and high-risk CHADS2 subgroups had higher 5-year mortality (hazard ratio [HR]: 2.22 [95% confidence interval {CI}: 1.78–2.77] and 3.66 [95% CI: 2.38–5.62], respectively), stroke recurrence (HR: 1.74 [95% CI: 1.09–2.79] and 1.71 [95% CI: 1.08–2.71], respectively), and cardiovascular events (HR: 1.78 [95% CI: 1.23–2.57] and 1.86 [95% CI: 1.30–2.67], respectively). Compared with the low-risk group, patients in the high-risk CHA2DS2-VASc subgroup also had higher 5-year mortality (HR: 3.56, 95% CI: 1.89–6.70), stroke recurrence (HR: 2.93, 95% CI: 1.30–6.61), and cardiovascular events (HR: 2.71, 95% CI: 1.49–4.95). Conclusions: Prestroke CHADS2 and CHA2DS2-VASc scores predict long-term stroke outcomes in non-AF patients with acute ischemic stroke. These scores may provide a simple way of stroke prognostic risk stratification among non-AF stroke patients.

[1]  K. Kario,et al.  CHADS2 score is associated with 3-month clinical outcomes after intravenous rt-PA therapy in stroke patients with atrial fibrillation: SAMURAI rt-PA Registry , 2011, Journal of the Neurological Sciences.

[2]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.

[3]  C. Allen.  Predicting the outcome of acute stroke: a prognostic score. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[4]  R. Collins,et al.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[5]  S. Johansson,et al.  Survival after stroke--the impact of CHADS2 score and atrial fibrillation. , 2010, International journal of cardiology.

[6]  Xin Qun Wang,et al.  A predictive risk model for outcomes of ischemic stroke. , 2000, Stroke.

[7]  L. Wilkins.  A Classification and Outline of Cerebrovascular Diseases II , 1975, Stroke.

[8]  H. Diener,et al.  Predictive value of the Essen Stroke Risk Score and Ankle Brachial Index in acute ischaemic stroke patients from 85 German stroke units , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[9]  J. Røislien,et al.  The "smoker's paradox" in patients with acute coronary syndrome: a systematic review , 2011, BMC medicine.

[10]  Gustavo Saposnik,et al.  IScore: A Risk Score to Predict Death Early After Hospitalization for an Acute Ischemic Stroke , 2011, Circulation.

[11]  D. Singer,et al.  Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention. , 2012, The American journal of cardiology.

[12]  G. Lip,et al.  Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10‐year follow‐up study , 2012, European journal of heart failure.

[13]  Myzoon Ali,et al.  Interconversion of the National Institutes of Health Stroke Scale and Scandinavian Stroke Scale in acute stroke. , 2009, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[14]  G. Saposnik.  An integer-based score to predict functional outcome in acute ischemic stroke: The ASTRAL score , 2012, Neurology.

[15]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[16]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.

[17]  M. Woodward,et al.  Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease. , 2005, European Heart Journal.

[18]  M. Dennis,et al.  Predicting functional outcome in acute stroke: comparison of a simple six variable model with other predictive systems and informal clinical prediction , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[20]  C. Nam,et al.  Early neurological outcomes according to CHADS2 score in stroke patients with non‐valvular atrial fibrillation , 2012, European journal of neurology.

[21]  S. Hatano,et al.  Experience from a multicentre stroke register: a preliminary report. , 1976, Bulletin of the World Health Organization.

[22]  Predicting outcome after acute ischemic stroke , 2004, Neurology.

[23]  B. Gage,et al.  Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin , 2004, Circulation.